SCLX Scilex Holding Company
SCLX Scilex Subsidiary Semnur Pharma Eyes $20M Private Placement Deal: More Details Inside
The proceeds of the agreement will be used to advance the second late-stage clinical trial for the development of SP-102, a viscous gel formulation of a widely used corticosteroid for epidural injections, for the treatment of lumbosacral radicular pain.
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt
Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt Oramed Pharmaceuticals Announces Restructuring of Scilex Holding Company Debt PR Newswire NEW YORK, Oct. 7, 2024 NEW...
PR Newswire·11mo ago
Scilex Holding Settles Lawsuit, Continues Litigation Against Ex-President
Scilex Holding Company (SCLX) has provided an update. Scilex Holding Company's subsidiary and Sorrento Therapeutics filed a lawsuit alleging breach...
TipRanks Financial Blog·1y ago
Scilex Holding Company Announces that the U.S. Bankruptcy Court has Extended the Lockup Period on Shares of Scilex Stock Previously Distributed by Sorrento to its Stockholders as a Dividend
PALO ALTO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex ), an innovative revenue-generating company focused on acquiring, developing and commercializing...
Globe Newswire·1y ago
Scilex Holding Company Announces New Out-of-Pocket Costs for Commercially Insured Patients
PALO ALTO, Calif., March 21, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex or Company ), an innovative revenue-generating company focused on acquiring, developing and...
Globe Newswire·1y ago
Scilex Holding Company Announces Seeking Approval from the FDA for Modification of the Gloperba Label to Provide Specific Dosing Guidance for Patients with Renal Impairment and Other Circumstances Where Dose Adjustment is Needed
Seek approval from the FDA for the modification of the Gloperba label to include its ability to utilize dosing flexibility of liquid formulation to address unmet medical needs and provide specific...
Globe Newswire·1y ago
Scilex Holding Company Announces a Settlement Agreement with Takeda Pharmaceuticals to Resolve the Paragraph IV Patent Infringement Lawsuit Relating to Scilex's Filing of a sNDA with the FDA Seeking to Expand the Label for its FDA-Approved Liquid Colchici
PALO ALTO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex or Company ), an innovative revenue-generating company focused on acquiring, developing and...
Globe Newswire·1y ago
Scilex Holding Company Announces Repayment in Full of the Remaining Balance of Convertible Debentures and Early Payment of the Senior Secured Promissory Note, Paving the Way for Future Growth and Innovation
PALO ALTO, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, Scilex ), an innovative revenue-generating company focused on acquiring, developing and commercializing...
Globe Newswire·1y ago
Scilex Holding Company Provides Responses to Product Composition Questions Related to its ELYXYB Patent in Canada for a New Drug Submission Under Review by Health Canada for the Approval of ELYXYB for Acute Treatment of Migraine With or Without Aura in
ELYXYB is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 According to market data from 2018, it...
Globe Newswire·1y ago